Can Fite Biopharma

Historical price data

Can Fite Biopharma's mission is to develop and commercialize novel, orally available therapeutics targeting the A3 adenosine receptor for oncology, inflammatory, and metabolic diseases. Its key achievements include establishing a robust pipeline with multiple Phase II/III candidates, securing significant out-licensing partnerships for its lead assets across major markets in Asia, Europe, and North America, and generating clinical proof-of-concept for its platform. The company's strategy is to advance its most promising programs through late-stage trials to achieve regulatory milestones, while continuing to monetize its pipeline through regional partnerships and non-dilutive funding to drive towards commercialization.

Platform of orally bioavailable small molecule agonists targeting the A3 adenosine receptor (A3AR), which is overexpressed in pathological cells, to induce apoptosis in cancer cells and modulate immune response in inflammatory diseases.

Faces entrenched competition in psoriasis from biologic and oral JAK inhibitors, in liver cancer from TKIs and immunotherapies, and in NASH from a crowded field of late-stage candidates. Its primary differentiation is the novel A3AR target, but it must demonstrate clear efficacy and safety advantages to secure market share.